ABCL
NASDAQAbCellera Biologics Inc.
Price$5.13+0.04 (+0.69%)
01:30 PM02:00 PM
News · 26 weeks34-56%
2025-12-142026-06-07
Mix1490d
- SEC Filings5(36%)
- Earnings3(21%)
- Other2(14%)
- Insider2(14%)
- Analyst1(7%)
- Leadership1(7%)
Latest news
25 items- SECAbCellera Biologics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- PRAbCellera Appoints Dr. Victor Sandor to its Board of DirectorsAbCellera (NASDAQ:ABCL) today announced the appointment of Victor Sandor, M.D.C.M, to its Board of Directors as an independent director. "Dr. Sandor is an experienced director and a distinguished medical oncologist with experience in building companies and bringing innovative medicines to patients in need," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "I am pleased to welcome Dr. Sandor to AbCellera's Board of Directors and look forward to working with him." Before its acquisition by Pfizer Inc., Dr. Sandor served as Chief Medical Officer at Array BioPharma Inc. where he successfully secured approval of Braftovi® (encorafenib) and Mektovi® (binimetinib). Prior to joining Array
- INSIDERChief Financial Officer Booth Andrew exercised 250,000 shares at a strike of $0.19, increasing direct ownership by 128% to 445,600 units (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERDirector Montalbano John S. bought $95,400 worth of shares (20,000 units at $4.77), increasing direct ownership by 9% to 241,000 units (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- SECSEC Form 10-Q filed by AbCellera Biologics Inc.10-Q - AbCellera Biologics Inc. (0001703057) (Filer)
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- PRAbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635ABCL635 demonstrated a favorable tolerability profile, with no observed liver toxicity, and achieved potent and sustained reductions in biomarkers of target engagement. Ended Q1 2026 with total available liquidity of approximately $655 million. AbCellera (NASDAQ:ABCL) today announced financial results for the first quarter of 2026 and positive interim results from the Phase 1 portion of its ongoing Phase 1/2 clinical trial of ABCL635. ABCL635 is a potential first-in-class antibody targeting the neurokinin 3 receptor (NK3R) for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. All financial information in this press release is reported in U.S. dol
- SECAmendment: SEC Form SCHEDULE 13G/A filed by AbCellera Biologics Inc.SCHEDULE 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)
- PRAbCellera to Present at Upcoming Investor Conferences in May and June 2026AbCellera (NASDAQ:ABCL) today announced that the Company will present at the following investor conferences: Bank of America Health Care Conference, May 13, 2026 Jefferies Global Healthcare Conference in New York, June 4, 2026 A live audio webcast of each presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website closer to date. A replay will be available through the same link following the presentation. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women's health, immunolog
- ANALYSTCantor Fitzgerald initiated coverage on AbCellera Biologics with a new price targetCantor Fitzgerald initiated coverage of AbCellera Biologics with a rating of Overweight and set a new price target of $7.00
- SECSEC Form DEFA14A filed by AbCellera Biologics Inc.DEFA14A - AbCellera Biologics Inc. (0001703057) (Filer)
- SECSEC Form DEF 14A filed by AbCellera Biologics Inc.DEF 14A - AbCellera Biologics Inc. (0001703057) (Filer)
- PRAbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings CallAbCellera (NASDAQ:ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic target engagement data, during its first quarter 2026 earnings call on Monday, May 11, 2026. ABCL635 is a potential first-in-class antibody therapeutic targeting the neurokinin 3 receptor (NK3R) for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. It is currently being evaluated in a Phase 1/2 study, and the results of the ongoing multicenter, randomized, double-blind, placebo-controlled Phase 2 portion in postmenopausal women with moderate-
- PRAbCellera to Report First Quarter 2026 Financial Results on May 11, 2026AbCellera (NASDAQ:ABCL) will announce its first quarter 2026 financial results on Monday, May 11, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women's health, immunology, oncology, and more. For more in
- INSIDERLarge owner Thermopylae Holdings Ltd. bought $130,720 worth of shares (38,000 units at $3.44), increasing direct ownership by 0.07% to 56,134,097 units (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERLarge owner Thermopylae Holdings Ltd. bought $580,284 worth of shares (177,457 units at $3.27), increasing direct ownership by 0.32% to 56,096,097 units (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- INSIDERChief Financial Officer Booth Andrew bought $145,692 worth of shares (42,600 units at $3.42), increasing direct ownership by 28% to 195,600 units (SEC Form 4)4 - AbCellera Biologics Inc. (0001703057) (Issuer)
- SECSEC Form S-8 filed by AbCellera Biologics Inc.S-8 - AbCellera Biologics Inc. (0001703057) (Filer)
- SECSEC Form 10-K filed by AbCellera Biologics Inc.10-K - AbCellera Biologics Inc. (0001703057) (Filer)
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- PRAbCellera Reports Full Year 2025 Business ResultsAbCellera (NASDAQ:ABCL) today announced financial results for the full year 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "In 2025, AbCellera successfully delivered on all its corporate priorities, transitioned to a clinical-stage biotech company, and ended the year with approximately $700 million in available liquidity to execute on our strategy," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "We entered 2026 with a fully built platform, a growing pipeline with multiple potential first-in-class programs and important near-term clinical readouts, and sufficient liquidity to fund well beyond the next three years of p
- PRAbCellera to Present at Upcoming Investor Conferences in March and April 2026AbCellera (NASDAQ:ABCL) today announced that the Company will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference, March 4, 2026 KeyBanc Capital Markets Healthcare Forum, March 17, 2026 Bloom Burton & Co. Healthcare Investor Conference, April 21-22, 2026 A live audio webcast of each presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website closer to date. A replay will be available through the same link following the presentation. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines i
- PRAbCellera to Report Full Year 2025 Financial Results on February 24, 2026AbCellera (NASDAQ:ABCL) will announce its full year 2025 financial results on Tuesday, February 24, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please v
- SECAbCellera Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - AbCellera Biologics Inc. (0001703057) (Filer)
- PRAbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to MenopauseAbCellera (NASDAQ:ABCL) today announced that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635. ABCL635 is a potential first-in-class non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause. The transition to Phase 2 follows an interim review of safety, tolerability, and pharmacodynamic data from healthy volunteers from the Phase 1 portion of the study. The Phase 2 portion is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy of ABCL635 in reducing the frequency and severity of VMS in 80 postmenopausal women. "Advancing this program into P
ABCL FAQ
7 questionsWhat does AbCellera Biologics Inc. do?
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.Where does ABCL stock trade?
AbCellera Biologics Inc. (ABCL) is listed on NASDAQ.What sector and industry is ABCL in?
AbCellera Biologics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AbCellera Biologics Inc. go public?
AbCellera Biologics Inc. (ABCL) completed its IPO in 2020.What are analysts saying about ABCL?
AbCellera Biologics Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight with a $700.00 price target on 2026-05-05. Recent price targets range from $400.00 to $2000.00.What companies are similar to ABCL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ABCL side-by-side with any of them on Quantisnow.How can I track ABCL on Quantisnow?
Quantisnow aggregates AbCellera Biologics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABCL to receive live email and push alerts on every new disclosure.